Report library

Flutiform

Flutiform ([fluticasone propionate + formoterol fumarate]; Vectura/Mundipharma/Kyorin) is a pressurized metered-dose inhaler formulation which contains a combination of fluticasone propionate and formoterol.

February 16, 2018

Disease Analysis: Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability.

October 7, 2021

Cabometyx

Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple tyrosine kinases including MET, AXL, and vascular endothelial growth factor receptor (VEGFR).

September 9, 2019

Acne Prescribing Practices Pulse Survey

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.

November 29, 2016

Arcapta

Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

July 31, 2018

Market Spotlight: Erectile Dysfunction

This Market Spotlight report covers the Erectile Dysfunction market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

March 17, 2022

Identifying High-Growth Medical Technology Markets in SE Asia to 2023

China is such a dominant player in Asia that often time valuable markets of opportunity get ovelooked. This 154 page report provides a detailed statistical view of 10 significant medical device and technology markets in South East Asia worth £14 billion in 2019. Comprising a pdf report and data set in MS Excel™, the report is rich in stats, tables and graphs and covers market value, market growth in US$/local currency and per capita spending over the last 5 years with 5-year forecasts to 2023, a range of demographic and commercial indicators plus analysis of trade segments such as orthopaedic products, medical/surgical consumables and diagnostic imaging.

August 28, 2019

MVA-BN RSV

MVA-BN RSV is a vaccine based on a recombinant MVA vector which expresses the RSV F and G glycoproteins, as well as the internal N and M2 proteins.

October 5, 2018

Global Markets for Infection Control and Biosafety Products, October 2016

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global medical waste disposal, device reprocessing, standard and safety needle/syringe, sharps disposal, and sterilization equipment and services markets.

October 7, 2016

U.S. Ophthalmic Surgical Systems Market, April 2014

$3,750.00

This report discusses common ophthalmic diseases/disorders, prevalence, estimated U.S. procedure volumes, leading energy-based (laser and phacoemulsification, or “phaco”) ophthalmic surgical systems and their features, and novel technologies. A detailed U.S. market analysis, competitive analysis, and company profiles of selected U.S. competitors are also provided.

April 1, 2014

2015 Jardiance EMPA-REG CVOT Pulse

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).

November 1, 2015

Gleevec

Gleevec (imatinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor (TKI). The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation.

December 7, 2017

Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

April 13, 2022

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of selected next-generation prostate cancer diagnostics, biopsy, and minimally invasive treatments.

May 4, 2022

Market Spotlight: Norovirus

This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and an epidemiological overview.

February 17, 2022

Cyramza

Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.

September 9, 2019

Disease Analysis: NHL: Follicular Lymphoma

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs.

March 10, 2022

Yonsa

Yonsa (Churchill Pharmaceuticals) is an oral, ultramicrosize tablet formulation of abiraterone acetate that inhibits 17 alpha-hydroxylase (CYP17). The CYP17 family of enzymes catalyze the hydroxylation of intermediates involved in testosterone synthesis, a common driver of prostate cancer genesis and recurrence.

January 18, 2018

Brilinta

Brilinta (ticagrelor; AstraZeneca/The Medicines Company) is an antiplatelet agent designed to inhibit blood clot formation. It works by reversibly binding to the blood platelets’ adenosine diphosphate (ADP) P2Y12 receptor…

April 14, 2016

Macugen

Macugen (pegaptanib; Valeant/Pfizer) is a PEGylated oligonucleotide aptamer which binds selectively

to vascular endothelial growth factor (VEGF)-165, an isoform of VEGF found to induce angiogenesis

and increase vascular permeability (Natarajan, 2013).

April 7, 2016

Imlygic

Imlygic (talimogene laherparepvec; Amgen) is a gene-deleted oncolytic herpes simplex virus-1 (HSV-1) that encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF). Upon administration, Imlygic replicates selectively in tumor cells and generates GM-CSF.

May 23, 2018

Yescarta

Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.

January 30, 2019

Indonesia Pharmaceutical Market Dynamics

Kalbe Farma is the leading player by some margin, with a market share of 13% in 2011, while GlaxoSmithKline is the largest foreign player with a 3% share.

November 2, 2016

Cemiplimab

Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody

August 30, 2018

Tobi/Tobi Podhaler

Tobi and the next-generation Tobi Podhaler are the gold-standard inhaled antibiotic treatments for cystic fibrosis patients.

September 3, 2018

capivasertib

Capivasertib (AstraZeneca) is an orally active, highly selective Akt inhibitor that preferentially targets Akt isoforms 1–3. Akt is a key enzyme in the PI3K/Akt/mTOR tumor cell survival pathway and is dysregulated in a number of malignancies through loss of tumor suppressor phosphatase and tensin homolog (PTEN), acquisition of activating mutations in phosphatidylinositol-4,5-bisphosphate 3- kinase catalytic subunit alpha (PIK3CA) or AKT1, as well as amplification of PI3K.

February 26, 2020

U.S. Markets for General and Pelvic Endoscopic Surgery Products

$4,750.00

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, surgical procedure volumes, competitors, and opportunities in the U.S. General and Pelvic Endoscopic Surgery Products Market.

September 22, 2016

Opioids and Chronic Neuropathic Pain Management KOL Interview

Biomedtracker interviewed a neurologist based in the United States who currently treats over 1000 patients with chronic neuropathic pain per year to determine his current treatment practices for indications including fibromyalgia and views on the use of opioids and abuse-deterrent opioids.

March 9, 2017

Inpatient Infections Pulse

We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.

October 8, 2014

Zoladex

Zoladex (goserelin; AstraZeneca/TerSera Therapeutics) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”

January 18, 2018

Big Pharma Diversification Strategies

Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.

March 4, 2018

Market Spotlight: Tuberculosis (TB)

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals.

May 12, 2022

Potiga

The novelty and clinical efficacy of Potiga (ezogabine; GlaxoSmithKline) are its greatest strengths. Its

novel mechanism of action on potassium channels is a key clinical differentiator in the competitive

epilepsy market.

July 6, 2016

Orencia

Orencia (abatacept; Bristol-Myers Squibb/Ono Pharmaceutical) is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte antigen-4.

October 17, 2017

Market Spotlight: Celiac Disease

Datamonitor Healthcare estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.

April 7, 2022

Profitability Assessment of Branded Generic Inhalers

We set out to examine the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic and generic inhaled products.

October 31, 2016

Disease Analysis: Dyslipidemia

Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated low-density lipoprotein cholesterol (LDL-C) due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular (CV) disease, one of the world’s leading causes of morbidity and mortality, though differences in LDL particle morphology can also play a role. Other lipid level deviations in dyslipidemia include elevated triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C), elevated total cholesterol, and elevated non-HDL-C, a marker of cholesterol in all atherogenic lipoproteins

May 13, 2022

Venclexta

Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.

January 31, 2019

lefitolimod

Lefitolimod is a synthetic DNA-based immunomodulator that acts as a Toll-like receptor (TLR)9 agonist.

December 11, 2017

Germany Healthcare System Overview

Already high and rising healthcare expenditure coupled with unfavorable demographic dynamics are prompting the German government to introduce changes in order to ensure healthcare system sustainability.

November 2, 2016

Congestive Heart Failure Pulse Survey

The study was just closed early, as LCZ696 increased time to first occurrence of either

cardiovascular death or heart failure hospitalization, though details have not been released.

We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different

assumptions about what the study found.

April 1, 2014

Digital Health: Diabetes Apps and Virtual Coaching

$2,250.00

Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.

March 10, 2020

Disease Analysis: Renal Cell Carcinoma (RCC)

Sutent is set to lose ground due to both newer, more effective treatments and imminent biosimilar erosion. Previously the SOC across many treatment settings, the pivotal trials of several newer therapies, which include checkpoint inhibitors Keytruda, Opdivo, and Bavencio, and the RTK inhibitor Cabometyx, have demonstrated significant clinical benefit over Sutent in the first-line setting. Keytruda and Cabometyx have also demonstrated benefit over Sutent in subsequent-line settings.

March 28, 2022